In this 13-minute interview, Dr. Antoni Ribas of UCLA's Jonsson Comprehensive Cancer Center provides an overview of the latest positive advancements in the use of combination BRAF and MEK inhibition to treat metastic melanoma. These latest findings suggest strong support for testing the combination therapy in future human clinical trials, which Jonsson Cancer Center researchers hope to launch within two years.